LKPC(SH:600789)2023-10-25 16:00Financial Performance - The company's operating revenue for Q3 2023 reached ¥1,545,695,648.48, representing a year-on-year increase of 21.41%[4] - Net profit attributable to shareholders for Q3 2023 was ¥61,173,140.14, a significant increase of 166.82% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2023 was ¥53,961,590.88, up 532.47% year-on-year[4] - Basic earnings per share for Q3 2023 were ¥0.07, reflecting a 133.33% increase compared to the same period last year[5] - The weighted average return on equity for Q3 2023 was 1.81%, an increase of 1.05 percentage points year-on-year[5] - The company reported a net profit of CNY 828,484,815.51 for the first nine months of 2023, compared to CNY 684,830,129.37 for the same period in 2022, reflecting an increase of approximately 21.0%[16] Cash Flow - The company reported a cash flow from operating activities of ¥460,575,170.99 for the year-to-date, an increase of 64.04%[8] - Cash inflow from operating activities for the first nine months of 2023 was ¥3,814,495,258.54, compared to ¥3,442,080,755.07 in the same period of 2022, indicating a growth of 10.8%[22] - The net cash flow from operating activities for Q3 2023 was $460,575,170.99, an increase of 64.3% compared to $280,773,356.90 in Q3 2022[23] - Total cash outflow from operating activities amounted to $3,353,920,087.55, up from $3,161,307,398.17 in the previous year[23] - Cash inflow from financing activities totaled $1,741,939,494.68, compared to $1,139,920,267.49 in the same quarter last year, marking a 52.8% increase[23] Assets and Liabilities - Total assets at the end of Q3 2023 amounted to ¥8,608,485,494.91, a decrease of 1.37% from the end of the previous year[5] - As of September 30, 2023, the total assets of Shandong Lukang Pharmaceutical Co., Ltd. amounted to CNY 8,608,485,494.91, a decrease from CNY 8,727,665,447.53 at the end of 2022[15] - The company's current assets totaled CNY 3,457,188,012.33, down from CNY 3,508,825,519.23 at the end of 2022, indicating a decline of approximately 1.5%[14] - The total liabilities decreased to CNY 4,923,840,879.20 from CNY 5,220,496,898.35, a reduction of about 5.7%[16] - The company's equity attributable to shareholders rose to CNY 3,526,937,521.68 from CNY 3,356,856,234.48, an increase of approximately 5.0%[16] Operational Efficiency - The company has strengthened accounts receivable management, leading to improved cash collection rates and increased cash flow from new product launches[8] - Total operating costs for Q3 2023 were ¥4,571,950,527.78, up 15.4% from ¥3,964,621,044.42 in Q3 2022[19] - Operating profit for Q3 2023 was ¥221,180,370.25, up from ¥100,581,811.40 in Q3 2022, representing a growth of 119.9%[19] Research and Development - Research and development expenses for Q3 2023 totaled ¥229,676,790.19, an increase of 18.1% from ¥194,476,190.57 in Q3 2022[19] Taxation - Tax expenses for Q3 2023 were ¥21,892,232.06, compared to ¥7,154,979.51 in Q3 2022, reflecting an increase of 205.5%[20] - The company reported a total tax payment of $208,158,552.35, an increase from $153,877,364.36 in the previous year[23] Investment Activities - The company reported a total investment loss of ¥3,793,508.77 in Q3 2023, worsening from a loss of ¥2,071,891.16 in Q3 2022[19] - The net cash flow from investing activities was -$285,793,797.11, slightly worse than -$279,811,460.43 in Q3 2022[23] - The total cash outflow for investing activities was $285,913,055.55, compared to $279,853,060.43 in Q3 2022[23] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 108,689[9]